InMed Pharmaceuticals Inc (INM)vsUnited Therapeutics Corporation (UTHR)
INM
InMed Pharmaceuticals Inc
$1.43
0.00%
HEALTHCARE · Cap: $7.80M
UTHR
United Therapeutics Corporation
$527.91
+2.17%
HEALTHCARE · Cap: $22.64B
Smart Verdict
WallStSmart Research — data-driven comparison
United Therapeutics Corporation generates 63723% more annual revenue ($3.15B vs $4.94M). UTHR leads profitability with a 41.6% profit margin vs -172.2%. UTHR earns a higher WallStSmart Score of 61/100 (C+).
INM
Avoid32
out of 100
Grade: F
UTHR
Buy61
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for INM.
Margin of Safety
+0.9%
Fair Value
$480.11
Current Price
$527.91
$47.80 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Conservative balance sheet, low leverage
Keeps 42 of every $100 in revenue as profit
Strong operational efficiency at 42.2%
Safe zone — low bankruptcy risk
Every $100 of equity generates 20 in profit
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -143.8% — below average capital efficiency
Revenue declined 26.2%
Expensive relative to growth rate
Revenue declined 1.9%
Comparative Analysis Report
WallStSmart ResearchBull Case : INM
The strongest argument for INM centers on Price/Book, Debt/Equity.
Bull Case : UTHR
The strongest argument for UTHR centers on Profit Margin, Operating Margin, Altman Z-Score. Profitability is solid with margins at 41.6% and operating margin at 42.2%.
Bear Case : INM
The primary concerns for INM are EPS Growth, Market Cap, Return on Equity.
Bear Case : UTHR
The primary concerns for UTHR are PEG Ratio, Revenue Growth.
Key Dynamics to Monitor
INM profiles as a turnaround stock while UTHR is a declining play — different risk/reward profiles.
INM carries more volatility with a beta of 0.98 — expect wider price swings.
UTHR is growing revenue faster at -1.9% — sustainability is the question.
UTHR generates stronger free cash flow (206M), providing more financial flexibility.
Bottom Line
UTHR scores higher overall (61/100 vs 32/100), backed by strong 41.6% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
InMed Pharmaceuticals Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
InMed Pharmaceuticals Inc., a clinical-stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company is headquartered in Vancouver, Canada.
United Therapeutics Corporation
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
United Therapeutics Corporation, a biotechnology company, is dedicated to the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company is headquartered in Silver Spring, Maryland.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?